Maciej Cabanski

Effective “activated PI3Kδ syndrome”–targeted therapy with the PI3Kδ inhibitor leniolisib

V. Koneti Rao, Sharon Webster, Virgil A. S. H. Dalm et al. · Blood · 2017 · 276 citations · Full text

Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity

Thomas Dörner, Maximilian Posch, Yue Li et al. · Annals of the Rheumatic Diseases · 2019 · 189 citations

Enforced expression of miR-125b affects myelopoiesis by targeting multiple signaling pathways

Ewa Surdziel, Maciej Cabanski, Iris Dallmann et al. · Blood · 2011 · 90 citations

Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial

Martin Kaul, Peter End, Maciej Cabanski et al. · Clinical and Translational Science · 2021 · 74 citations · Full text

Cyt‐Geist: Current and Future Challenges in Cytometry: Reports of the CYTO 2018 Conference Workshops

Kamila Czechowska, Joanne Lannigan, Lili Wang et al. · Cytometry Part A · 2019 · 26 citations · Full text